多中心注册研究中经导管二尖瓣植入与传统再次手术治疗退化二尖瓣人工瓣膜和瓣环的比较
该多中心注册研究纳入10家德国心脏中心2014至2019年273例因二尖瓣人工瓣膜/瓣环退化接受再次手术的患者,经倾向性评分匹配为79对,比较经导管二尖瓣瓣中瓣植入与再次二尖瓣置换的30天/中期死亡率,发现两组死亡率无差异,中度及以上三尖瓣反流是全因、30天和中期死亡率的预测因素。
要点
- 两组30天/中期死亡率无差异,观察死亡率均低于预测值。
- 中度及以上三尖瓣反流是全因死亡(OR 4.36)、30天死亡(OR 3.76)和中期死亡(OR 4.30)的预测因素。
- 再次手术可处理心房颤动或三尖瓣反流等合并情况。
核心结论
- 两组观察死亡率均低于预测值,再次手术可治疗心房颤动或三尖瓣反流等合并情况,三尖瓣反流是两组全因、30天和中期死亡率的预测因素。
研究设计与样本
- 由10家德国心脏中心提供数据的倾向性评分匹配回顾性分析,2014至2019年共273例患者(经导管二尖瓣瓣中瓣植入79例,再次二尖瓣置换194例),匹配后79对。
- 主要终点为30天/中期死亡率,围术期结局按二尖瓣学术研究联盟标准评估。
主要发现
- 经导管组EuroSCORE II预测风险为15.7 ± 13.7%,再次手术组为15.0% ± 12.7%(P = .5336)。
- 经导管组年龄更大(74.73岁 vs 72.2岁;P = .0030),心房颤动发生率更高(54例 vs 40例;P = .0233)。
- 重度三尖瓣反流发生率相似(经导管组17.95% vs 再次手术组14.10%;P = .1741)。
- 经导管组68例既往接受二尖瓣置换,再次手术组41例既往接受瓣膜修复(P < .0001);狭窄是主要退化机制(经导管组42例 vs 再次手术组22例;P < .0005)。
- 两组30天/中期死亡率无差异;中度及以上三尖瓣反流是全因死亡(OR 4.36;P = .0011)、30天死亡(OR 3.76;P = .0180)和中期死亡(OR 4.30;P = .0378)的预测因素,与分组无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Degeneration of mitral prostheses/rings may be treated by redo surgery, and, recently, by transcatheter valve-in-valve/ring implantation. This multicenter registry presents results of transcatheter valve-in-valve and repeat surgery for prostheses/rings degeneration. METHODS: Data provided by 10 German heart centers underwent propensity score-matched retrospective analysis. The primary endpoint was 30-day/midterm mortality. Perioperative outcome was assessed according to the Mitral Valve Academic Research Consortium criteria. Further, the influence of moderate or greater tricuspid regurgitation (TR) on 30-day/midterm mortality was analyzed. RESULTS: Between 2014 and 2019, 273 patients (79 transcatheter mitral valve-in-valve [TM-ViV] and 194 redo mitral valve replacement [Re-MVR]) underwent repeat procedure for mitral prosthesis/ring degeneration. Propensity score matching distinguished 79 patient pairs. European System for Cardiac Operative Risk Evaluation (EuroSCORE) II-predicted risk was 15.7 ± 13.7% in the TM-ViV group and 15.0% ± 12.7% in the Re-MVR group (P = .5336). TM-ViV patients were older (74.73 vs 72.2 years; P = .0030) and had higher incidence of atrial fibrillation (54 vs 40 patients; P = .0233). Severe TR incidence was similar (17.95% in TM-ViV vs 14.10%; P = .1741). Sixty-eight TM-ViV patients previously underwent mitral valve replacement, whereas 41 Re-MVR patients underwent valve repair (P < .0001). Stenosis was the leading degeneration mechanism in 42 TM-ViV versus 22 Re-MVR patients (P < .0005). The 30-day/midterm mortality did not differ between groups. Moderate or greater TR was a predictor of total (odds ratio [OR], 4.36; P = .0011), 30-day (OR, 3.76; P = .0180), and midterm mortality (OR, 4.30; P = .0378), irrespective of group. CONCLUSIONS: In both groups, observed mortality was less than predicted. Redo surgery enabled treatment of concomitant conditions, such as atrial fibrillation or TR. TR was shown to be a predictor of total, 30-day, and midterm mortality in both groups.
引用
- Szlapka M, Hausmann H, Timm J, et al. Transcatheter mitral valve implantation versus conventional redo surgery for degenerated mitral valve prostheses and rings in a multicenter registry. J Thorac Cardiovasc Surg. 2022. PMID: 36088142. doi:10.1016/j.jtcvs.2022.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。